Protein a Resin Market Report 2026

The protein a resin market size has grown strongly in recent years. It will grow from $1.78 billion in 2025 to $1.95 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to growth of biopharmaceutical manufacturing, expansion of antibody-based therapeutics, increasing use of affinity chromatography, rising investments in biologics r&d, availability of recombinant protein a technologies.

The protein a resin market size is expected to see rapid growth in the next few years. It will grow to $2.87 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing biologics pipeline development, rising adoption of continuous manufacturing, expansion of biosimilar production, growing focus on cost-efficient purification processes, increasing demand for high-throughput chromatography. Major trends in the forecast period include increasing use of high-capacity protein a resins, rising adoption of single-use chromatography systems, growing demand for monoclonal antibody production, expansion of continuous bioprocessing, enhanced focus on resin reusability.

The increased R&D investments in pharmaceutical companies are expected to propel the growth of the protein A resin market forward. R&D refers to the process of researching and developing new drugs, therapies, technologies, or services to improve patient health. Protein A resin is used in several chromatography assays in pharmaceutical development as a chromatography medium. For instance, in February 2024, according to IQVIA, a US-based public company and healthcare analytics provider, global biopharmaceutical R&D funding reached $72 billion in 2023, up from $61 billion in 2022. Consequently, increased R&D investments in pharmaceutical companies are driving the growth of the protein A resin market.

Major companies in the protein resin market are focusing on developing high-reliability technologies, including polymer technology, to boost productivity and tackle the specific challenges of purifying complex biomolecules in biopharmaceutical manufacturing. Polymer technology in protein A resin enhances the performance and stability of resins in chromatography processes for antibody purification, improving binding capacity, chemical resistance, and longevity. For instance, in September 2024, JSR Life Sciences, a US-based company that develops and manufactures various biomedical materials, launched Amsphere A+, a next-generation protein A chromatography resin designed to improve antibody drug purification. This new resin offers superior binding capacity, stability, and efficiency compared to its predecessor, Amsphere A3. The innovation aims to support the increasing complexity of antibody drug production, particularly for bispecific antibodies and antibody-drug conjugates, utilizing a proprietary protein ligand and advanced polymer technology to enhance production efficiency.

In April 2023, Sino Biological, a China-based company specializing in recombinant protein production and antibody development, acquired SignalChem Biotech Inc. for $48 million. This acquisition aims to enhance Sino Biological’s expertise in bioactive enzyme production, which is crucial for advancing drug discovery and development, and to expand its product range and research services. By leveraging specialized enzyme platforms, Sino Biological seeks to better serve the global life sciences community. SignalChem Biotech Inc. is a Canada-based company focused on the research, development, and production of innovative and high-quality human recombinant cell signaling products.

Major companies operating in the protein a resin market are Repligen Corporation, Tosoh Corporation, Sartorius AG, Thermo Fisher Scientific, Bio-Rad Laboratories, Merck KGaA, Kaneka Corporation, JSR Corporation, Mitsubishi Chemical Group, GenScript Biotech Corporation, Asahi Kasei Corporation, Toray Industries, Inc., YMC Co., Ltd., Chisso Corporation, Sekisui Chemical Co., Ltd., Daicel Corporation, Purolite Life Sciences, Jiangsu Tiance Biotech Co., Ltd., Suzhou Nanomicro Technology Co., Ltd., Beijing Sepax Technologies, Inc.

North America was the largest region in the Protein A Resin market in 2025. Europe is expected to be the fastest-growing region in the protein A resin market report during the forecast period. The regions covered in the protein a resin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the protein a resin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The protein A resin market consists of sales of fiber-based fibro prismA units, agarose-based protein A, and ion exchange chromatography resins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.